Purpose: Although cigarette smoking and alcohol use are known risk factors for squamous cell carcinoma of head and neck (SCCHN), only a few exposed individuals develop this disease, suggesting an individual susceptibility. In this study, we investigated the associations between genetically determined DNA repair capacity (DRC) for removing tobacco-induced DNA adducts and risk of SCCHN and tumor characteristics.
Squamous cell carcinoma of head and neck (SCCHN), including cancers of the oral cavity, pharynx, and larynx but excluding nasopharyngeal carcinoma, accounted for over half a million cancer cases worldwide annually (1) (2) (3) . Almost 75% of those cases were in men (2) . In the United States, SCCHN accounts for ∼3% of all newly diagnosed cancer cases annually; although the incidence rate had been declining since the early 1980s, the estimated number of new cases had been increasing, from 40,500 in 2006 to 48,010 in 2009, according to the American Cancer Society (4-7). 5 Although cigarette smoking and alcohol use are major risk factors for SCCHN (8, 9) , individual susceptibility must play a role because only a small fraction of smokers and alcohol users develops SCCHN in their lifetime.
Cigarette smoke contains numerous carcinogenic chemicals that can cause damage to DNA. For example, benzo(a)pyrene is a classic DNA-damaging carcinogen that is found in tobacco smoke as well as in the environment as a result of fuel combustion (10) . Its bioactivated form, benzo(a)pyrene diol epoxide (BPDE), can cause irreversible damage to DNA by forming DNA adducts through covalent binding or oxidation (11, 12) . In living cells, BPDEinduced DNA adducts can block transcription of essential genes, if the DNA is not repaired efficiently by the nucleotide excision repair (NER) pathway (13) , a major and well-developed cellular repair mechanism. To measure the cellular DNA repair capacity (DRC) phenotype, Athas et al. (14) developed an in vitro host-cell reactivation (HCR) assay that measures the extent to which the cellular repair system removes the lesions in DNA that block the transcription of an active gene. This assay has been successfully applied to epidemiologic studies of susceptibility to cancers induced by UV light (15, 16) or tobacco carcinogens (17) (18) (19) (20) including cancers of the skin, breast, lung, and head and neck by our group and others (21) (22) (23) (24) (25) .
In an early pilot study of 55 SCCHN patients and 61 cancer-free controls, we reported that the patients exhibited a suboptimal DRC for removing BPDE-induced DNA adducts, compared with that in cancer-free controls (18) . Based on that study and the xeroderma pigmentosum (XP) paradigm of inherited defect in NER coupled with high risk of cancers (26, 27) , we hypothesized that there is variation in DRC among the general population and that individuals with genetically inherited low DRC are predisposed to SCCHN. To further validate and confirm the association between DRC and the risk of SCCHN, we conducted a large, independent case-control study including 744 patients with SCCHN and 753 cancer-free controls who were non-Hispanic whites, none of whom had been included in the early pilot study (18) . We also investigated the association of DRC with tumor characteristics in 744 SCCHN patients.
Materials and Methods
Study subjects. The study population has been described elsewhere (28) . Patients with newly diagnosed, histopathologically confirmed SCCHN were recruited from The University of Texas M.D. Anderson Cancer Center between September 1998 and March 2006. The exclusion criteria were prior surgery (other than diagnostic biopsies), chemotherapy, radiation therapy, or any blood transfusion during the preceding 6 mo. Although ∼95% of eligible subjects contacted chose to participate, patients included in this study represented only ∼35% of all SCCHN patients seen during the study period at M.D. Anderson. This is because it is a tertiary hospital that treats many patients mostly presenting with recurrence or seeking a second opinion. Cancer-free controls were recruited from among individuals who were not seeking health care but accompanying other cancer patients to M.D. Anderson; they were biologically unrelated to the cases or one another included in this study. Potential controls first completed a short screening sheet that provided demographic information for matching and determining their willingness and eligibility to participate in this study. Those who gave oral consent were selected to match the cases by age (±5 y), sex, and ethnicity. Among the willing respondents first contacted for recruitment, the response rate was ∼90%. Reasons for not participating included ineligibility and reluctance to provide a blood sample needed for laboratory testing for DRC.
A written informed consent was obtained from eligible patients and controls, after which an interviewer administered a structured questionnaire to collect demographic data and information about risk factors for SCCHN, such as smoking, alcohol use, and family history of first-degree relatives with cancer. Subjects who had smoked <100 cigarettes during their lifetime were defined as never smokers; others were considered smokers, of which those who had stopped smoking >12 mo were defined as former smokers and the remaining was considered current smokers. Pack-years of smoking (cigarettes per day/20 × years smoked) were calculated for smokers. Subjects who had drunk alcoholic beverages at least weekly for 1 y were defined as drinkers, of which those who had stopped drinking >12 mo were defined as former drinkers and the remaining was considered current drinkers; others were considered never drinkers. Drink-years [lifetime drinking in kilogram = ethanol (in grams) per week × years of drinking × 52/1,000] were also calculated. A family history of cancer in first-degree relatives was defined as any selfreported cancer in the subject's parents, siblings, or children. Each subject donated a 30-mL blood sample drawn into a heparinized tube (Becton Dikinson) before receiving treatment for cases and when consent was given for controls. The study protocol was approved by the M.D. Anderson Institutional Review Board.
The HCR assay for DRC. The HCR assay for DRC has been described previously (17) . Because it is not practical to collect target tissues for this assay or the target tissue may have somatic changes induced by exposures, such as cigarette smoking and alcohol use, we used peripheral blood as the surrogate tissue, which is easily to obtain in a noninvasive way. It has been reported that there is a correlation in DRC between lymphocytes and target cells in XP patients (29) , suggesting that inherited DRC could be reflected in different tissues of the same individual. Therefore, in our assay protocol, we use viable cryopreserved T lymphocytes that were isolated from whole blood samples by Ficoll gradient centrifugation within 24 h after the blood was drawn. The purified pCMV-CAT plasmids (a gift from Lawrence Grossman of Johns Hopkins University, Baltimore, MD; ref. 14) were treated with BPDE (Midwest Research Institute) at a final concentration of 60 μmol/L (14, 18), repurified, and stored at −20°C until they were used for the HCR assays. When enough stored lymphocyte samples had accumulated, the HCR assays were done in batches (each having ∼20 samples with approximately equal numbers of cases and controls). The performers doing the DRC assay have been blinded to case-control status of each sample. Specifically, the cells were thawed, cultured,
Translational Relevance
This molecular epidemiologic study provides evidence of cellular DNA repair phenotype as a genetic susceptibility biomarker for squamous cell carcinoma of head and neck. This study contributes to our understanding of the role of nucleotide excision repair in the etiology of squamous cell carcinoma of head and neck, and could be used for identifying individuals at risk of developing smoking-related cancers, who might benefit from targeted cancer prevention programs. and stimulated by phytohemagglutinin for 72 h, followed by transfection with untreated and BPDE-treated pCMV-CAT plasmids. Transfections were done using the DEAE-dextran (Pharmacia Biotech, Inc.) method (30) . After transfection, another 40-h incubation was allowed for the repair of damaged plasmids and CAT gene expression. Then, the cell pellets were collected and washed twice with 1.5 mL of TBS and were resuspended in 31.5 μL of 0.25 moles of TBS in a 1.5-mL tube. The cells were lysed by three 10-min cycles of freezing and thawing in a dry ice-ethanol bath and a 37°C water bath.
Because a single unrepaired DNA adduct can effectively block transcription of the reporter gene CAT (31), any chloramphenicol acetyltransferase (CAT) activity, measured in cells transfected with treated plasmids relative to that measured in cells transfected with untreated plasmids, provides a quantitative measurement of the cells' capacity to remove BPDE-induced adducts that had inactivated the reporter gene (14) . We then measured the activity of the repaired CAT gene using a scintillation counter to determine the formation of 14, 17, 18). Four EBV-immortalized human lymphoblastic cell lines from the Human Genetic Mutant Cell Repositories were used as assay controls, including two apparently repair-proficient phenotype cell lines (GM00892B and GM00131A) and two repair-deficient XP cell lines [GM02345B (XP-A) and GM02246B (XP-C)]. Under our experimental conditions, the DRC of normal control cell lines was ∼20% for GM00892B and 15% for GM00131A, compared with only <1% for GM02345B (XP-A) and ∼1% for GM02246B (XP-C); therefore, administering a BPDE dose of 60 μmol/L can differentiate between cells that are either repair proficient or repair deficient.
Statistical analysis. Differences in the distributions of categorical variables between cases and controls were evaluated using the χ 2 test. DRC was analyzed as a continuous variable before and after natural logarithmic transformation. Student's t test or ANOVA was used to compare the differences in DRC among groups. The blastogenic rate (percentage of cells that were stimulated by phytohemagglutinin), the baseline CAT expression level (in cpm), and cell storage time (in months) were also recorded for comparison between cases and controls. In addition, we used the medians and quartiles of DRC values in the control group as cutoff values to create dummy variables and to estimate crude odds ratios (OR) and 95% confidence intervals (CI). Because we did not use an exact 1:1 matching ratio but used frequency matching instead, unconditional multivariate logistic regression models were done to calculate ORs and CIs with adjustment for the covariates (i.e., age, sex, smoking status, drinking status, blastogenic rate, cell storage time, baseline CAT expression, and family history of cancer).
We assessed the association between DRC and SCCHN risk and performed a stratification analysis followed by an assessment of interactions between DRC and selected variables. A more-than-multiplicative interaction was suggested when OR 11 > OR 10 × OR 01 , in which OR 11 was the OR when both factors were present, OR 01 was the OR when only factor 1 was present, and OR 10 was the OR when only factor 2 was present. Similarly, a morethan-additive interaction was indicated if OR 11 > OR 10 + OR 01 − 1. First, we evaluated the interactions indicating a more-than-multiplicative relationship using standard unconditional logistic regression models. If the test for multiplicative interaction was not rejected, we further tested for additive interactions using a bootstrapping test of the goodness of fit of the null hypothesis of an additive model against an alternative hypothesis of no interaction that permitted an additive interaction (Stata 10.1 software; StataCorp LP).
To assess the effect of DRC on SCCHN risk prediction, we constructed two risk models: the covariates model including only epidemiologic variables [e.g., age, sex, smoking and drinking status (never versus ever), and family history of any cancer in first-degree relatives] and the DRC model including the epidemiologic variables plus assay characteristics and DRC (continuous variable). We first calculated the predicted probability of developing SCCHN using logistic models for each participant, which resulted in two estimates of risk for each participant (one for the covariates model and the other for the DRC model). We then calculated the area under the receiver operating characteristic (ROC) curve (AUC) in the two models (32) to assess the improvement of DRC in risk prediction. We further calculated the AUC upon stratification by smoking status (never versus ever). All statistical tests were two sided, and P < 0.05 was considered significant. We analyzed all data, except for additive model, using SAS software (version 9.1.3; SAS Institute).
Results
Characteristics of the study population. As shown in Table 1 , the cases and controls seemed to be adequately frequency matched for age and sex. The mean age was 55.93 years (range, 18-90 years) for the cases and 56.07 years (range, 20-85 years) for the controls (P = 0.801; Table 2 ), with ∼75% of males for both cases and controls. Patients were more likely than controls to be ever smokers (73.0% versus 53.0%) and alcohol users (74.3% versus 58.8%), but self-reported family history of cancer was not a significant risk factor for SCCHN in this study population (Table 1) , indicating a possible overmatching for family history possibly as a result of our hospital-based control selection design. Of 744 patients with SCCHN, 199 (26.7%) had primary tumors of the oral cavity; 418 (56.2%) presented with primary tumors of the pharynx (oropharynx and hypopharynx); (Table 1) . Association between DRC and risk of SCCHN. When DRC was analyzed as a continuous variable, the mean DRC was 8.84% in cases and 9.97% in controls, with an average reduction of 11% in DRC in patients with SCCHN (P < 0.0001; Table 2 ). This difference remained significant after natural log transformation of the data (P < 0.0001; Table  2 ). Because the results without transformation were qualitatively similar to those with natural log transformation, we used untransformed DRC values in the remainder of the analyses. The mean DRC among the 753 controls (9.97%) was similar to what we reported for 316 unrelated control subjects (9.8%) in another independent study (17) in which we used the same HCR assay; these findings suggest good reproducibility of the assay. The interpersonal variation in DRC among the 753 control subjects (coefficient of variation) was 26.2%, compared with 47.5% among the previously reported 488 controls (20) , suggesting more stable or improved DRC estimates as the sample size increased.
As shown in Table 2 , there were statistically significant differences in blastogenic rate (P = 0.0006) and cell storage time (P < 0.0001) between cases and controls. However, the baseline CAT expression was not statistically different (P = 0.628), suggesting that the cell status and cell storage time did not have significant effects on transfection rate or cell growth-two factors that were thought to be most likely to have an effect on DRC measurements of the HCR assay. The average of baseline CAT activity in cells transfected with untreated plasmid (∼40,000 cpm) was nearly 400 times greater than that of background CAT activity (∼100 cpm), suggesting that the transfections were adequate and successful. Furthermore, we found that the DRC was not statistically significantly correlated with the blastogenic rate (r = −0.028, P = 0.447 in controls, r = 0.030, P = 0.411 in cases) and cell storage time (r = 0.032, P = 0.385 in controls, r = 0.023, P = 0.530 in cases), as we reported before (15) . However, the correlation between DRC and baseline CAT expression was statistically significant in 753 cancer-free controls (r = 0.217, P < 0.0001) and in 744 patients (r = 0.247, P < 0.0001). Nevertheless, all of these assay-related variables were also adjusted for subsequent multivariate logistic regression analyses that evaluated the overall and stratified main effects of DRC on risk of SCCHN.
When continuous DRC values were used in the logistic regression model without or with adjustment for all covariates, the crude and adjusted ORs were significantly elevated by 18% and 19%, respectively, at a 1% decrement of DRC (OR, 1.18; 95% CI, 1.12-1.22 and OR, 1.19; 95% CI, 1.13-1.24, respectively; Table 3 ). When DRC values were categorized by the median or quartile of the controls, the decreased DRC was consistently associated with increased Abbreviations: T, tumor; N, lymph node. *Two-sided χ 2 tests for differences in the distributions of the numbers of each category between cases and controls. † Two-sided Student's t tests for the differences in DRC between cases and controls. ‡ DRC was measured as the ratio of reporter gene activity in cells transfected with damaged plasmids to that in cells transfected with undamaged plasmids (×100%). § One-way ANOVA or two-sided Student's t tests for the differences in DRC among or between subgroups in cases and controls. ∥ Defined as number of packs of cigarettes smoked per day × number of years of smoking.
¶ Defined as total kilograms of ethanol in beer, wine, and liquor that drunk up to the year when the subjects participated in the study. Table 3 ). Stratification analysis of DRC by selected variables and tumor characteristics. The stratification analysis of continuous DRC measurements revealed that all subgroups of patients consistently exhibited significantly lower mean DRC than did controls except for the two subgroups with medium levels of smoking pack-years (Table 1 ). In controls, men had significantly higher DRC than did women (P = 0.036). There were no other significant differences in DRC by subgroups of selected variables for both cases and controls; nor was there a significant association of DRC with pack-years of smoking or drink-years (Table 1) . Interestingly, we found that the stratified mean values of DRC and 95% CI by smoking status exhibited opposite trends in cases and controls as shown in Fig. 1 , with the P value for a trend test of 0.396 for the cases and 0.044 for the controls. However, there were no significant differences in DRC by tumor characteristics, including anatomic site and tumor stage (tumor, lymph node, and overall: P = 0.956 for tumor, P = 0.478 for lymph node, and P = 0.322 for overall) as shown in Table 1 , suggesting that DRC is unlikely to be a tumor marker.
Interactions between DRC and selected variables. We further assessed possible interactions, on both multiplicative and additive scales, between DRC and the variables listed in Table 1 . The multiplicative interaction was tested when we included the interaction term (i.e., dichotomized DRC × each risk factor) in the multivariate logistic regression model that also included the main effect of DRC and other covariates. We did not find a more-than-multiplicative interaction between these variables and DRC in relation to SCCHN risk. However, when we did bootstrapping tests, we found that smoking status (never versus ever) had significant additive interactions with DRC (P = 0.030) and age group (≤55 years versus >55 years) showed a borderline modification on DRC (P = 0.056; data not shown). To further unravel these additive interactions, we stratified the adjusted ORs by two age groups as well as never and ever smokers (Fig. 2) . It was apparent that all ORs in groups of younger age (≤55 years) and never smokers were greater than those in groups of older age (>55 years) and ever smokers (Fig. 2) .
Risk prediction. To evaluate the performance of DRC in SCCHN risk prediction models, we calculated the AUC. Figure 3 shows the ROC curves that measures the DRC performance in two dimensions. The AUC was significantly improved in the model that included DRC compared with the model that did not: AUC = 0.72 (95% CI, 0.70-0.75) versus 0.65 (95% CI, 0.62-0.67; P < 0.001). The improvements of AUC in the DRC models were more evident in never smokers (from 0.58 to 0.70) than in ever smokers (from 0.62 to 0.71; Fig. 3 ).
Discussion
In this large, independent case-control study, we confirmed our previously reported association between suboptimal DRC phenotype and risk of developing SCCHN (18) . Our additional analyses of the AUC for the role of DRC in risk prediction further suggested that DRC provided significant improvement in the risk prediction model we tested in the present study. Therefore, we conclude that DRC for removing BPDE-induced DNA adducts, as measured by the HCR assay in T lymphocytes, may be an independent susceptibility biomarker for the risk of smoking-related cancers because this finding is also consistent with our previous findings on DRC and lung cancer risk (17, 20) . However, in this expanded study, it was also confirmed that DRC was not a tumor marker because this phenotype was not associated with tumor sites and stages. In recent years, numerous biomarkers for genetic susceptibility have been applied to molecular epidemiologic studies of smoking-related cancers (33, 34) . Among these markers, polymorphisms, particularly the putatively functional ones, of genes in DNA repair pathways have been investigated most extensively in association studies of cancers (33, 34) . However, most positive results in studies with small samples were not substantiated in later larger studies. In our analysis of 829 SCCHN patients and 854 cancer-free controls from the same study population, we (35) . These results suggest that association studies of a single SNP or SNPs in a single gene may not be sufficient to detect the risk associated with low-penetrance genetic variants. In contrast, some phenotypic biomarkers that can detect functional differences are likely to be determined by a group of genetic variants in many genes involved in the same pathway. The DRC phenotype for removing BPDE-induced damage as measured in this study may represent the sum of the functions of various enzymes involved in the NER pathway-that is, a pathway-specific measurement of the NER capacity (14, 36) that has an advantage over any single SNP or SNPs in a single gene in association studies. The study on the correlation between DRC phenotype and genotypes in risk of head and neck cancer with a much larger sample size as well as the genome-wide association of this study population are under intensive investigation in our laboratory. It has been reported that DRC is reversely correlated with age in healthy, cancer-free subjects (16, 21, 24, 37, 38) , but this reverse correlation was not evident in larger population-based studies using peripheral blood lymphocytes (15, 17, 23, 39) . In the present study, we did not observe a correlation between DRC and age in either controls (r = −0.008, P = 0.827) or patients (r = 0.059, P = 0.110); however, younger cases (ages ≤55 years) with a low DRC (<9.8%) exhibited a 3-fold greater risk of developing SCCHN compared with older subjects (ages >55 years) with a high DRC (≥9.8%). This finding was consistent with what we found in studies of basal cell carcinoma (39) and lung cancer (17) , in which young subjects had increased cancer risks associated with low DRC, suggesting a genetic basis of low DRC for susceptibility to cancers that is often characteristic of an early age of onset. Therefore, the present study provides additional support for a role of suboptimal DRC in the etiology of cancer.
Previous studies have also suggested that women have a higher risk of developing smoking-related cancers than do men who were at similar levels of exposure (40, 41) . In our study population, we found a significantly lower DRC in female control subjects than in male control subjects and a nonsignificantly lower DRC in female patients than in male patients, which are also consistent with our previously reported findings (17) .
In the present study, as we expected, more cases than controls were ever smokers or ever alcohol drinkers, but we did not detect differences in DRC values by status or quantity of cigarette smoking and alcohol drinking in either case or control subjects. However, we found an additive effect modification of smoking status on DRC, which was more evident in never smokers, suggesting that suboptimal DRC may play a more important role in the risk of SCCHN in never smokers than in ever smokers, as shown also in the ROC curves and by calculating the AUC in the present study, although they may have previously experienced low exposure (never smokers in this study were defined as those smoked <100 cigarettes or they may have been exposed to passive smoke; ref. 42) . Recently, the phenotypic and genotypic markers have been tentatively added to risk prediction models. For example, mammographic density has been applied to the modification of the Gail model (43) for prediction of breast cancer risk; some studies have investigated the contribution of genetic variations to cardiovascular disease in risk prediction models (44, 45) ; and we also reported the improvement on prediction of lung cancer risk with DRC in the AUC model (46) . Clearly, the present study found a much better improvement in AUC by the DRC phenotypic marker compared with those published models, and this is the first study to apply AUC to SCCHN risk prediction with inclusion of the DRC.
The present study has both strengths and limitations. First, to our knowledge, besides our large molecular epidemiologic study on lung cancer risk using the HCR assay to assess DRC for removing BPDE-induced damage (47, 48) , this is the second largest independent study of the HCR assay for DRC in cancer susceptibility. To overcome possible selection bias, we applied a stringent frequency-matching strategy in recruiting cases and controls to control for potentially confounding variables. Second, our cases had received no treatment before blood samples were drawn, which should have obviated any effect of treatment on the function of lymphocytes used for the HCR assay. Third, our HCR assay is a direct measure of damage-repair kinetics in functionally intact cells free from the cytotoxic effects of the DNA-damaging agent, BPDE, which was used to damage the plasmids, the substrate of the cellular repair machinery. Therefore, this HCR assay using unaffected T lymphocytes is an optimal phenotypic assay to determine genetic susceptibility to smoking-related cancers in association studies. Until this assay has been validated in longitudinal studies as a reliable marker for cancer risk, this assay remains a research tool rather than a clinical test for detecting individual DRC.
Because we used a case-control study design, it is impossible to exclude the effect of the disease on the measured DRC phenotype, although the XP paradigm has established the cause-effect and temporal relationships between reduced DRC and subsequent cancer risk (27) . However, a recent longitudinal study has shown that there is no evidence for an effect of disease status on the DRC phenotype as measured by the comet assay, when the assays applied to cell lines derived from lymphocytes collected before and after cancer diagnosis (49) . Furthermore, because the DRC was not measured in cells from the target tissue, we did not know whether there was a correlation between measurements obtained from lymphocytes and target tissues in this study population, although such a correlation has been established in XP patients (29) .
In conclusion, the DRC for removing BPDE-induced DNA adducts, as measured by the HCR assay in primary lymphocytes, seems to be a good, reliable biomarker for the measurement of genetic susceptibility for smoking-related cancers. However, genetic determinants of the DRC phenotype needs to be further illustrated, preferably by a genome-wide approach (50) . If our results are validated in large, prospective cohort studies, this DRC phenotype could be used for identifying individuals at risk of developing smoking-related cancers, who might benefit from targeted cancer prevention programs.
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